Member Info for Diversified

Summers, had you of said yesterday, ‘I told you so’, you would of been wrong by end of day. Let’s hope that applies today, key is to focus on fundamentals. Unless your trading of course.

To add, with Twist having over $300m in cash and with links to big biotech funders from America at its side. At Fab current market cap, it’s platform/library is very vulnerable to a takeover approach imo.

Yes you can. Dummy sells are available at 185p.

I think this is more likely to go up given the massive hammer candlestick from yesterday, and based purely on the fundamentals and pending news of a neutralizing therapeutic.

See Twist Biopharma that has seen its market cap increase from $1b to $3b based on its own neutralizing antibodies.

Scope here is massive with market cap at only £50m. Market is completely overlooking the potential of this company.

The hammer candlestick with a long lower shadow represents a major bullish reversal which is likely to be confirmed tomorrow.

Very relaxed about this one.

250 odd trades (buys) soaked up a dozen and half large late reported sells. Sellers pot is not endless and when it dries up this will bolt forward in a sustainable and fairly fast manner. Especially with all the near term newsflow.

It’s very exciting.

Not to mention this:

‘ As a result of the May 2020 resource update, and the favourable ammonium thiosulfate gold and silver recovery tests reported in June 2020, the Company initiated a RC drilling programme targeting potential extensions to the gold and silver mineralisation identified in the report, as well as targeting areas of Inferred mineralisation in an attempt to upgrade Inferred to Measured and Indicated resources.’

The recovery tests in June will Influence the inferred, measured and indicated resources to. Massive update can be expected.

Considerable newsflow to come to

Great to see results coming from remap-cap as at this rate they will reporting of T before solidarity trial.

My expeditions for ST is still end of October. Will be good to see the HIBISCUS study initiated

To add, we need all the treatments, vaccines, tests we possibly can to keep the economy and our way of life as sustainable/normal as possible.

Truamakine is a critical care treatment.

40 years after the first vaccine for flu was administered, one person dies every 40 seconds from the flu. I personally provide little attention to the significance of a vaccine.

I have a friend who works for Roche, they have a 7/8 year plan for COVID which shows what the big boys think of the longevity of the virus.

Presents a massive opportunity hear. New investor as of yesterday and especially grateful for the notes provided. It’s not the easiest company to research given the level of technical data to get your head around. But the fact this is flying under radar is what has presented a great opportunity to buy regardless of its recent run since April. Upcoming news flow should see this run continue.

I am very surprised how they have managed to hold this back with the no. of buy trades, but again I am not complaining as a new investor. More time to accumulate.

Great volume yesterday, should be interesting today as some would of taken profit and will want to see the price drop. Fun and games will continue today no doubt as the second earn in offer must have been presented by now and we await news when in my view is imminent.

Read into it what you want but last year the presentation was for analysts only but this year is open to all investors and is followed by a live Q&A session to new only cover financial results but operating results.

We normally get a Martins update every three months and by my calcs the next is due next week.

Is completely understated and as of yet discussed on this forum for obvious reasons, with the prominence of T and it’s imminent trial results.

My point being, to have looked back at the share price and it’s inflection points, imo, a lot of the current valuation has to do with Clevergen. Today’s results from 4D and the comparative increase in the market cap for a ‘Part A’ readout goes to show how Clevergen can and will rise to prominence in the near future with its next update imminent.

Imo, market cap still significantly undervalues where FARN is in the cycle with its pipeline.

https://twitter.com/kakape/status/1297857905346084864?s=21

With a late sell of on SNG having little to no bearing here. I can only think that the stock has sold off for one of three reasons:

1. Tree shake
2. COPD results are underwhelming making it a one tick pony (COVID19 only)
3. Market realizes phase three trials are needed before approval and the timeline has been somewhat batted down the line

I think to some extent it has a bearing on sentiment here today, but today’s reversal was impressive.

We are at critical point of care and not at point of diagnosis.

Seems to be a lot of chancers, first time posters trying to underplay the stock. Many sitting with a position they feel comfortable with and will ignore the games.

Very strong reversal today which was good to see

https://pubmed.ncbi.nlm.nih.gov/32661006/

Significant reduction in 14 day discharge and 25% reduction in mortality in this small study. Reason enough to now be part of the biggest trials globally.

Unfortunately many are not buying the positivity around plasma:

https://twitter.com/erictopol/status/1297583093285494785?s=21

The more treatments that are available the better it is for all evolved. What is interesting about the plasma is it is effective for those that receive treatment within 3 days of diagnosis.

What we need is treatments for those who are in a critical condition, this is where traumakine comes in. T was never meant to treat Covid, but in the event we receive positive data, it will only go to support/derisk it’s future phase III ADRS trials.

https://twitter.com/presssec/status/1297373454262571008?s=21

https://twitter.com/karitikkinen/status/1297203927667159040?s=21

For me this confirms my original expectation of late October read out for Interferon.

As I said in earlier post, plenty of additional interest to peak interest here in the interim.